Results 171 to 180 of about 79,448 (358)

Endophthalmitis Outbreak Associated with Repackaged Bevacizumab

Emerging Infectious Diseases, 2015
Laura S. Edison, Hope O. Dishman, Melissa Tobin-D’Angelo, C. Richard Allen, Alice Y. Guh, Cherie L. Drenzek   +5 more
doaj   +1 more source

Stability and Dissolution Behavior Changes After Drug Compounding for Pediatric Cardiovascular Pharmacotherapy. [PDF]

Pharmaceutics
Saito J, Yamatani A, Kojima Y, Nakakuni M, Nakano K, Hirose K, Nakamura H, Hanawa T, Akabane M.   +8 more
europepmc   +1 more source

DNA-Encoded Library Screening Identifies CDK2-Targeting Lead Compounds with Favorable Drug-like Properties for Anticancer Development

Liping Zhou, Yong Ju, Zhijuan Cao, Sheng Cai, Jiayuan Su, Jianzhong Lu   +5 more
openalex   +1 more source

Clarification of Signal Transduction via Drug Receptor and Drug Development. Molecular pharmacological analysis of signal transduction by synthetic compounds.

, 1997
Hiroyoshi Hidaka
openalex   +2 more sources

Marine Compound Xyloketal B as a Potential Drug Development Target for Neuroprotection [PDF]

, 2018
Haifan Gong, Zhengwei Luo, Wenliang Chen, Zhong‐Ping Feng, Guan‐Lei Wang, Hong‐Shuo Sun   +5 more
openalex   +1 more source

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

Molecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad, Rhiannon Newman, Elmira Khabusheva, Sofia Aakko, Eric Durand, Mahesh Tambe, Heikki Kuusanmäki, Alun Parsons, Juho J. Miettinen, Komal Kumar Javarappa, Ezgi June Olgac, Nemo Ikonen, Mika Kontro, Kimmo Porkka, Heiko Maacke, Janghee Woo, Ensar Halilovic, Caroline A. Heckman   +17 more
wiley   +1 more source

The neural crest‐associated gene ERRFI1 is involved in melanoma progression and resistance toward targeted therapy

Molecular Oncology, EarlyView.
ERRFI1, a neural crest (NC)‐associated gene, was upregulated in melanoma and negatively correlated with the expression of melanocytic differentiation markers and the susceptibility of melanoma cells toward BRAF inhibitors (BRAFi). Knocking down ERRFI1 significantly increased the sensitivity of melanoma cells to BRAFi.
Nina Wang, Qian Sun, Daniel Novak, Lei Zhu, Juliane Poelchen, Tamara Steinfass, Yiman Wang, Viktor Umansky, Jochen Utikal   +8 more
wiley   +1 more source

Bioinformatics-Driven Drug Discovery for Breast Cancer: A Focus on Natural Compounds [PDF]

Ruquaiya Quddus
openalex   +1 more source

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

Molecular Oncology, EarlyView.
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece, Giulio Lovato, Ilaria Cela, Arianna Mercatelli, Benedetta Ferro, Jussi Nikkola, Sara Pagotto, Tommaso Grottola, Vincenzo De Laurenzi, Rossella Cicchetti, Antonio Marchetti, Luigi Schips, Rossano Lattanzio, Stefano Iacobelli, Emily Capone, Peter Black, Mads Daugaard, Michele Marchioni, Gianluca Sala   +18 more
wiley   +1 more source

Multifactorial Causes of Tacrolimus Errors: Confusion With Strength/Formulation, Look-Alike Names, Preparation Errors, and More Ensuring Safety of Recipes for Drug Compounding Please, no more teaspoon dosing. [PDF]

Hosp Pharm, 2018
Cohen MR, Smetzer JL.
europepmc   +1 more source